By Jason Derry --
Peptimmune and Novartis Sign $500 Million Deal
Peptimmune Inc. and Novartis AG recently announced a licensing deal for Peptimmune's multiple sclerosis drug candidate, PI-2301. The deal gives Novartis an exclusive license to the drug candidate. Novartis will assume all responsibilities relative to clinical development, manufacturing, and marketing of PI-2301. The deal could be worth up to $500 million for Peptimmune if certain milestones are met. In addition, Peptimmune will be entitled to royalties on drug sales.
BMS to License HCV Therapy from Zymogenetics
Bristol-Myers Squibb (BMS) and ZymoGenetics recently announced a licensing deal for ZymoGenetics' hepatitis C therapy PEG-interferon lambda. BMS will pay ZymoGenetics $85 million upfront and a license fee of $20 million for 2009. ZymoGenetics will also be entitled to further payments based on certain milestones events. In all, the deal could be worth up to $1.1 billion for ZymoGenetics.
Merck to License MS Drug
Merck KGaA recently announced that it has entered a licensing agreement with Apitope, a British biotech company, to license Apitope's multiple sclerosis drug, ATX-MS-1467. Merck has reported that it will pay Apitope up to $204.8 million in upfront payments and possible milestone payments. Apitope will also be entitled to royalties. Apitope's press release regarding the agreement can be viewed here.